We conclude that neither clinically approved daratumumab nor recently developed nanobody-derived hcAbs provide a second mode of action against MM cells and that therefore there remains a quest for double action CD38-inhibitory antibodies. This evidence concerns the gene CD38 and Miyoshi myopathy.